The STELVIO trial, a game changer for bronchoscopic lung volume reduction in patients with severe emphysema. Issue 1 (March 2020)

• Record Type: Journal Article
• Authors: Posthuma, Rein; Vanfleteren, Lowie E.G.W.
• Is Part Of: Breathe. Volume 16:Issue 1(2020)
• Publication Date: 2020-03
• Subjects: Respiratory organs -- Diseases; Respiratory organs -- Diseases -- Treatment; Periodicals; 616.2005
• DOI: 10.1183/20734735.0004-2020
• Languages: English
• ISSNs: 1810-6838

Abstract

Chronic obstructive pulmonary disease (COPD) is characterised by persistent respiratory symptoms and airflow limitation, which is caused by small airway disease (bronchiolitis) and alveolar destruction (emphysema) [1]. Patients primarily suffering from severe emphysema are often limited in exercise capacity due to the consequences of hyperinflation [2]. The STELVIO trial was crucial to ensure that bronchoscopic lung volume reduction using one-way valves has evolved from an experimental intervention into a state-of-the-art treatment option for specific patients with advanced emphysema http://bit.ly/2IgMrsp